Maxigen Biotech Inc.

TWSE:1783 Stock Report

Market Cap: NT$3.6b

Maxigen Biotech Management

Management criteria checks 3/4

Maxigen Biotech's CEO is Ching-Ting Chen, appointed in Sep 2021, has a tenure of 4.92 years. directly owns 0.17% of the company’s shares, worth NT$6.01M. The average tenure of the management team and the board of directors is 3.4 years and 5.1 years respectively.

Key information

Ching-Ting Chen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure4.9yrs
CEO ownership0.2%
Management average tenure3.4yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Analysis Article • Nov 20

Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft Earnings

Maxigen Biotech Inc.'s ( TWSE:1783 ) recent weak earnings report didn't cause a big stock movement. We think that...
Analysis Article • Mar 28

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Despite posting some strong earnings, the market for Maxigen Biotech Inc.'s ( TWSE:1783 ) stock hasn't moved much. We...
Analysis Article • Apr 22

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Could Maxigen Biotech Inc. ( TPE:1783 ) be an attractive dividend share to own for the long haul? Investors are often...
Analysis Article • Apr 01

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

The market shrugged off Maxigen Biotech Inc.'s ( TPE:1783 ) solid earnings report. We think that investors might be...
Analysis Article • Mar 16

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Maxigen Biotech's (TPE:1783) stock is up by a considerable 26% over the past three months. Given that stock prices are...
Analysis Article • Feb 23

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Buying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some are...
Analysis Article • Feb 02

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...
Analysis Article • Jan 10

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Today we'll take a closer look at Maxigen Biotech Inc. ( TPE:1783 ) from a dividend investor's perspective. Owning a...
Analysis Article • Dec 14

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Maxigen Biotech (TPE:1783) has had a rough three months with its share price down 7.2%. However, the company's...
Analysis Article • Nov 22

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results...

CEO Compensation Analysis

How has Ching-Ting Chen's remuneration changed compared to Maxigen Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

NT$291m

Mar 31 2026n/an/a

NT$271m

Dec 31 2025n/an/a

NT$265m

Sep 30 2025n/an/a

NT$234m

Jun 30 2025n/an/a

NT$208m

Mar 31 2025n/an/a

NT$209m

Dec 31 2024NT$6mNT$2m

NT$190m

Sep 30 2024n/an/a

NT$155m

Jun 30 2024n/an/a

NT$147m

Mar 31 2024n/an/a

NT$150m

Dec 31 2023NT$7mNT$4m

NT$166m

Sep 30 2023n/an/a

NT$191m

Jun 30 2023n/an/a

NT$192m

Mar 31 2023n/an/a

NT$163m

Dec 31 2022n/an/a

NT$139m

Sep 30 2022n/an/a

NT$110m

Jun 30 2022n/an/a

NT$99m

Mar 31 2022n/an/a

NT$87m

Dec 31 2021NT$1mNT$540k

NT$88m

Compensation vs Market: Insufficient data to establish whether Ching-Ting's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Ching-Ting's compensation has been consistent with company performance over the past year.

CEO

Ching-Ting Chen

4.9yrs
Tenure
NT$6,062,000
Compensation

Ms. Ching-Ting Chen is Institutional Director of TCI Co. Ltd. from June 25, 2024 and serves as Head of Research & Design Center since February 5, 2020. She is General manager of TCI CO., Ltd.She has been...

Leadership Team

NamePositionTenureCompensationOwnership
Ching-Ting Chen
GM & Representative Director4.9yrsNT$6.06m0.17%
NT$ 6.0m
Ruei Yi Wu
Financial Officer & Accounting Officer3.4yrsNT$1.65mno data
Hao-Jun Wang
Supervisor of the Preci-sion Manufacturing Center2.8yrsNT$2.41mno data
Karen Lee
Senior Manager of Administrationno datano datano data
3.4yrs
Average Tenure

Experienced Management: 1783's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ching-Ting Chen
GM & Representative Director4.8yrsNT$6.06m0.17%
NT$ 6.0m
Yung-Hsiang Lin
Chairman of the Board5.1yrsNT$6.68m0.62%
NT$ 22.6m
Xiu-Yuan Li
Representative Director11.2yrsNT$650.00kno data
Zhen-Zhen Fu
Representative Director5.1yrsNT$650.00kno data
Song Yuan Liao
Independent Director5.1yrsNT$770.00kno data
Zhong-Ming Zeng
Independent Director5.1yrsNT$770.00kno data
Shih-Ming Lai
Director4.2yrsNT$650.00kno data
Shih-An Chen
Independent Director1.2yrsno datano data
Chih-Cheng Tsai
Representative Director2.2yrsNT$20.00kno data
5.1yrs
Average Tenure

Experienced Board: 1783's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/21 13:30
End of Day Share Price 2026/08/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Maxigen Biotech Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Regina LeeCapital Securities Corporation
Hsiu Chi LinMasterlink Securities Investment Advisory